# PROTACs Sector

Canonical URL: https://biopharmsignal.com/sector/protacs

PROTACs includes companies using targeted protein degradation to eliminate disease-causing proteins rather than simply inhibit them. This category is followed closely because it represents a differentiated drug-design strategy with potential advantages in select oncology and immunology settings.

Companies currently grouped under PROTACs: 3

## Recent Sector News

- 2026-09-03 11:00 EST — CCCC — [C4 Therapeutics to Present New Biomarker Data on the Immunomodulatory Effects of Cemsidomide in Combination with Dexamethasone from its Phase 1 Relapsed/Refractory Multiple Myeloma Trial at the 23rd International Myeloma Society (IMS) Annual Meeting](https://biopharmsignal.com/news/CCCC/c4-therapeutics-to-present-new-biomarker-data-on-the-immunomodulatory-effects-of-c45b1594) — Source: C4 Therapeutics
- 2026-09-02 20:01 EST — KYMR — [Kymera Therapeutics to Participate in Upcoming September Investor Conferences](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-participate-in-upcoming-september-investor-conferences-235282c6) — Source: Kymera
- 2026-09-01 12:00 EST — NRIX — [Nurix Therapeutics to Participate in Upcoming September Investor Conferences](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-participate-in-upcoming-september-investor-conferences-e57a80b8) — Source: Nurix Therapeutics
- 2026-09-01 11:00 EST — KYMR — [Kymera Therapeutics Announces Presentations on KT-621, a First-in-Class, Oral STAT6 Degrader, at the European Respiratory Society and European Academy of Dermatology & Venereology Congresses](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-presentations-on-kt-621-a-first-in-class-oral-stat-0df98d42) — Source: Kymera
- 2026-08-20 11:00 EST — NRIX — [Nurix Therapeutics Announces Appointment of Wes Burwell  as Chief Human Resources Officer](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-appointment-of-wes-burwell-as-chief-human-resources-77c7a23e) — Source: Nurix Therapeutics
- 2026-08-11 11:00 EST — CCCC — [C4 Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights](https://biopharmsignal.com/news/CCCC/c4-therapeutics-reports-second-quarter-2026-financial-results-and-recent-busines-a932eb01) — Source: C4 Therapeutics
- 2026-08-10 20:01 EST — CCCC — [C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/CCCC/c4-therapeutics-announces-inducement-grant-under-nasdaq-listing-rule-5635-c-4-8be48fb6) — Source: C4 Therapeutics
- 2026-08-05 11:00 EST — KYMR — [Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2026-financial-results-and-provides-26a4f5e5) — Source: Kymera
- 2026-08-04 11:00 EST — NRIX — [Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader](https://biopharmsignal.com/news/NRIX/nurix-announces-10-million-milestone-payment-associated-with-initiation-of-a-pha-7c23128a) — Source: Nurix Therapeutics
- 2026-08-04 05:00 EST — NRIX — [Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-first-patient-enrolled-in-registrational-phase-3-da-2b8297cd) — Source: Nurix Therapeutics
- 2026-07-28 20:01 EST — KYMR — [Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-report-second-quarter-2026-financial-results-on-august-5--5364bc95) — Source: Kymera
- 2026-07-27 20:01 EST — KYMR — [Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-terence-rooney-md-as-chief-medical-officer-93d7b265) — Source: Kymera
- 2026-07-21 20:01 EST — NRIX — [Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-announces-hsr-clearance-of-global-collaboration-with-roche-to-2860a8c3) — Source: Nurix Therapeutics
- 2026-07-09 20:01 EST — NRIX — [Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-reports-second-quarter-2026-financial-results-and-provides-co-84944bef) — Source: Nurix Therapeutics
- 2026-07-07 11:00 EST — KYMR — [Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-elizabeth-laws-ph-d-as-senior-vice-president-global-f322a3cc) — Source: Kymera
- 2026-06-25 11:00 EST — KYMR — [Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-completes-enrollment-in-the-phase-2b-broaden2-trial-of-kt-62-eddcfec5) — Source: Kymera
- 2026-06-24 20:01 EST — KYMR — [Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-felix-j-baker-ph-d-as-chairman-of-the-board-of-dire-f3d892d4) — Source: Kymera
- 2026-06-12 11:00 EST — KYMR — [Kymera Therapeutics Presents Phase 1 Data in Healthy Japanese Adults for KT-621, a First-in-Class Oral STAT6 Degrader, at the Japanese Dermatological Association Annual Meeting](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-presents-phase-1-data-in-healthy-japanese-adults-for-kt-621--a0403465) — Source: Kymera
- 2026-06-11 11:00 EST — NRIX — [Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy](https://biopharmsignal.com/news/NRIX/nurix-therapeutics-to-report-updated-phase-1a-b-results-for-btk-degrader-bexobru-e82ed85b) — Source: Nurix Therapeutics
- 2026-06-11 11:00 EST — CCCC — [C4 Therapeutics Presents Phase 1 Data at European Hematology Association (EHA) 2026 Congress Highlighting Cemsidomide as a Potential Best-in-Class IKZF1/3 Degrader for Multiple Myeloma in Heavily Pretreated Relapsed/Refractory Population](https://biopharmsignal.com/news/CCCC/c4-therapeutics-presents-phase-1-data-at-european-hematology-association-eha-202-2551b658) — Source: C4 Therapeutics

## Companies

- [CCCC](https://biopharmsignal.com/company/CCCC) — C4 Therapeutics
- [KYMR](https://biopharmsignal.com/company/KYMR) — Kymera
- [NRIX](https://biopharmsignal.com/company/NRIX) — Nurix Therapeutics